To prospectively compare the response to treatment with a self-expandable esophageal stent loaded with iodine 125 ( 125 I) seeds for intraluminal brachytherapy versus the response to treatment with a conventional selfexpandable covered stent in patients with advanced esophageal cancer.
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To prospectively compare the response to treatment with a self-expandable esophageal stent loaded with iodine 125 ( 125 I) seeds for intraluminal brachytherapy versus the response to treatment with a conventional selfexpandable covered stent in patients with advanced esophageal cancer.
The study protocol was approved by the institutional ethics committee, and informed consent was obtained from each patient. Patients from one institution who had dysphagia caused by inoperable esophageal cancer were randomly assigned to receive treatment with a stent loaded with 125I seeds (irradiation stent group) or a conventional covered stent (control group). After stent implantation, the outcomes were measured in terms of relief of dysphagia, survival time, and complications related to the procedure. Dysphagia was assigned a grade. A P value of less than .05 was considered to indicate a signifi cant difference.
The stent was successfully placed in the diseased esophagus in all 53 patients (27 patients in the irradiation stent group and 26 patients in the control group). The dysphagia grades significantly improved in both groups within the 1st month after stent placement but were better in the irradiation stent group than in the control group after 2 months (P .05). The median and mean survival times were better in the irradiation stent group than in the control group, and the differences were signifi cant (P .001). Hemorrhage occurred in 16 (30%) patients in both groups combined during follow-up.
In patients with advanced esophageal cancer, treatment with an esophageal stent loaded with 125 I seeds, compared with that with a conventional covered stent, has potential benefi t in that it allows a slightly longer relief of dysphagia and extended survival.
Results

Methods
【 Abstract 】
Objective
Conclusions
Dysphagia is the predominant symptom of patients with inoperable esophageal cancer. To relieve the dysphagia and improve the quality of life of such patients, brachytherapy has previously been used (1, 2) .
Recently, stent placement has been widely accepted to be an option for palliation of the symptoms caused by esophageal strictures (3) (4) (5) (6) . However, recurrence of neoplastic stricture remains a challenge after stent placement. To combine the advantages of the immediate relief of esophageal dysphagia with stent placement and radiation therapy with brachytherapy, an esophageal stent loaded with iodine 125 ( 125 I) seeds has been developed. The technical feasibility and safety with this stent have been demonstrated as adequate in a healthy rabbit model (7) . Thus, the purpose of our study was to prospectively compare the response to treatment with a self-expandable esophageal stent loaded with 125 I seeds for intraluminal brachytherapy versus the response to treatment with a conventional self-expandable covered stent in patients with advanced esophageal cancer.
Materials and Methods Patients
The study protocol was approved by our institutional ethics committee, and informed consent was obtained All diagnoses were histopathologically established by using endoscopic biopsy. Dysphagia was assigned a grade as follows: grade 0, the patient had the ability to eat a normal diet; grade 1, the patient had the ability to eat some solid food; grade 2, the patient had the ability to eat semisolid foods only; grade 3, the patient had the ability to swallow liquids only; and grade 4, the patient had complete obstruction (8) .
Stent Preparation
The esophageal irradiation stent combined a selfexpandable covered or uncovered esophageal stent (MTN; Nanjing MicroInvasive Medical, Nanjing, China) and 125 I radioactive seeds (Fig 1) . In 22 patients, covered stents were used, and in fi ve, uncovered stents were used. insertion between the two groups ( Table 1) .
The mean, median, and length of follow-up in the irradiation stent group versus the control group were 7.2 versus 3.3 months, 6.0 versus 3.5 months, and 15.0 versus 6.7
months, respectively.
The diameter of the stent used in the irradiation stent and the control groups ranged from 18 to 20 mm, and the length ranged from 80 to 120 mm. Twenty-two covered seed loss occurred during the process of irradiation stent insertion and deployment (Fig 2a) . All patients tolerated stent placement well. Follow-up esophagography 3 days after stent placement showed that all stents expanded fully without stent migration.
N o p a t i e n t s i n e i t h e r g r o u p w e r e t r e a t e d w i t h chemotherapy prior to or following the stent placement.
However, eight patients in the irradiation stent group and seven patients in the control group had received at least a course of support treatment of traditional Chinese medicine prior to or after stent implantation.
Follow-up Imaging and Endoscopy
Emission CT examinations in the irradiation stent group performed at 1 and 3 months after stent placement showed no radiation seed displacement to other parts of the body (Fig 2b) . 
S t e n t r e s t e n o s i s w a s d e m o n s t r a t e d b y u s i n g esophagographic and/or endoscopic examinations
in eight patients in the irradiation stent group and in six patients in the control group. These patients had recurrent dysphagia after stent placement during follow-up. The stent restenosis occurred later in the irradiation stent group than in the control group (4.75 vs 2.00 months) ( Table 2 ). There was a significant difference in the onset 
Dysphagia Grades
The dysphagia grades (Fig 3) improved greatly in both the irradiation stent group (mean, 1.07 ± 0.27) and the control group (mean, 1.04 ± 0.20); 3 days after stent placement, there was no signifi cant difference between the two groups (P >.99, Kruskal-Wallis test). The dysphagia was equally well palliated within the 1st month after stent placement in both groups; for the irradiation stent group, the mean grade was 1.22 ± 0.42, and for the control group, the mean grade was 1.17 ± 0.38 (P =.732, KruskalWallis test). Thereafter, the dysphagia grades increased in both groups, but more substantially in the control group than in the irradiation stent group. After 2 months, there was a significant difference (P < .05). Although the dysphagia returned slowly, beginning at 1 month after stent placement in the irradiation stent group, the dysphagia grades indicated that the patients were able to eat without serious difficulty during the follow-up of 6 months.
Side Effects and Complications
No severe procedure-related complications occurred in any case. The side effects and complications during follow-up are presented in Table 3 . Hemorrhage occurred in 16 (30%) patients (nine patients Figure 3 : Mean dysphagia grade during followup and before stent placement. Within 1st month after stent placement, dysphagia was equally well palliated in both groups: For irradiation stent group, mean grade was 1.22±0.42; for control group, mean grade was 1.17±0.38 (P+ .732, Kruskal-Wallis test). Thereafter, dysphagia grades increased in both groups but more substantially in control group than in irradiation stent group. After 2 months, there was a signifi cant difference (P<.05). in the irradiation stent group and seven patients in the control group) during follow-up. Eleven (21%) patients (six patients in the irradiation stent group and fi ve patients in the control group) died from acute massive hemorrhage.
Six patients in the irradiation stent group died at 3, 3, 4, 7, 7, and 10 months; fi ve patients in the control group died at 8 days, 10 days, 1 month, 2 months, and 2 months; and the remaining fi ve patients (three patients in the irradiation stent group and two patients in the control group) survived the bleeding. There was no significant difference in the incidence of hemorrhage between the two groups.
No complete migration of stents was demonstrated, but partial stent migration was detected in fi ve patients (two patients in the irradiation stent group and three patients in the control group) at 1 month following stent insertion.
In two of them (one in each group), one additional conventional covered stent was implanted. The differences between both measures of survival in the two groups were signifi cant (P < .001, log-rank test) (Fig 4) . However, the radiation dosimetry with such a stent in the esophageal lumen is difficult to precisely measure and plan. Therefore, a proper dose of 125 I seeds is important.
Discussion
The average applied radioactivity of 370.0 MBq in our study was determined by taking into account data in our own previous experiments in rabbits (7) , as well as experiences with intraluminal brachytherapy. There were no severe complications related to the radiation dose in our series of patients, and the tumors improved with therapy, suggesting that the selected dose was appropriate.
Although the dysphagia grades improved immediately after the stent placement in both groups, they remained Hemorrhage is the most important late complication.
The incidence of late hemorrhage varies from 9.7% to 12.3% (11,13). The incidence in our series of patients was higher compared with that reported in the literature; 16 (30%) patients had hemorrhage during follow-up, and 11
(21%) of them died from acute massive hemorrhage at 8 days to 10 months after stent placement. However, the incidence of hemorrhage between the two groups was not signifi cantly different. Although the actual mechanism of hemorrhage with esophageal stent placement is uncertain, it is believed that hemorrhage may be caused by the exertion of pressure by the stent on the tumor, on the normal mucosa of the esophagus, or on both (14) .
Animal experimental data indicate that ischemic changes that result from compression by the stent wires may cause esophageal ulcerations (7) . The hemorrhage may be related to previous radiation therapy, different types of stents used, or different sites of stent placement (4, 13, 15, 16) . It is interesting that there is no significant difference in hemorrhage between the patients with or without radioactive seeds, although the patients with radioactive seeds survived longer. This result may be due to a protective effect on bleeding from the tumor through tumor debulking and an injury effect on the tumor vasculature by the radiation of brachytherapy, as well as the increasing risk caused by the expanding force of a stent.
However, two patients in the control group died of massive hemorrhage in 8 and 10 days after placement, compared with no deaths within 3 months in the irradiation group. These two patients had sudden uncontrolled hematemesis. Our best explanation for the deaths is aortic perforation caused by stent meshes, although autopsy was not performed in these patients.
There has been a report of a case caused by perforation of the aorta from stent penetration (16).
Esophageal perforation or tracheoesophageal fistula occurs in 2.7%-7.3% of patients after esophageal stent placement (4, 13, 15, 16) . Such a complication may be increased with an irradiation stent because of the radiation effect on the esophageal wall. However, tracheoesophageal fistula occurred in only one patient in our series. An irradiation stent was used in this patient, but the site of the fistula was at least 2.0 cm away from the proximal end of the stent. Therefore, we do not think this complication is related to the irradiation stent.
Radiation safety protection measures should be taken by physicians, patients, and anyone who approaches the patient with the irradiation stent. Several protection measures for radiation safety were taken in our study. Because it is difficult tomeasure the absorbed dose in the lumen of an organ such as the esophagus, we did not obtain the exact dosimetry in the patient with an irradiation stent or in people approaching that patient in our study. However, the safety of radiation with the implantation of 125 I seeds has been accepted in brachytherapy f o r c a n c e r s s u c h a s p r o s t a t e c a n c e r . M o r e o v e r , n o complications related to radiation were found in our series of patients.
Our study had certain limitations. could not provide quantitative data related to radiation therapy.
Second, the quality of life, which is an important measure of outcomes for the palliative treatment of malignancies such as inoperable esophageal cancer, was not measured in our study.
In conclusion, with increased survival combined with decreased dysphagia grades, our study findings indicate that therapy with an irradiation stent loaded with 125 I seeds has potential benefit in patients with advanced esophageal cancer. We believe further investigation of this treatment modality is indicated.
